Bipolar 1 Depression: An Evidence-Based Approach to Clinical Practice
Bipolar 1 Depression: An Evidence-Based Approach to Clinical Practice
Andrew J. Cutler, MD
CEO and Medical Director
Florida Clinical Research Center, LLC
Courtesy Assistant Professor of Psychiatry
University of Florida
Jon W. Draud, MS, MD
Clinical Professor of Psychiatry
University of Tennessee College of Medicine
Medical Director of Psychiatry, Addiction, Medicine Services
Baptist Hospital, Nashville, Tennessee
Middle Tennessee Medical Center
This activity was developed for primary care physicians, psychiatrists, physician assistants, psychiatric nurses, psychologists, and other healthcare professionals who seek to improve their care for patients with mental health disorders and the outcomes resulting from that care.
- Employ evidence-based tools to identify and differentiate between unipolar and bipolar depression in the clinical setting.
- Discuss the pathophysiology of bipolar I depression, including neurobiological and systemic factors, and influence on comorbidities.
- Initiate evidence-based medication treatment for bipolar I depression, paying special attention to the benefit vs risk profiles of available agents.
- Implement measures aimed at addressing safety and tolerability concerns that result in either partial or complete nonadherence.
This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit:
- Upon launching the webcast, you will be redirected to http://www.medscape.org/viewarticle/775763 where you will need to either create or log into your Medscape account. All program components will be completed on the Medscape site.
- Read the intended learners, learning objectives, and author disclosures.
- Study the educational content online.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Release Date: December 20, 2012
Expiration Date: December 20, 2013
Estimated time to complete: 1.25 hours
For CME/CE questions regarding this educational activity, please call 609-371-1137.
For technical assistance, please contact CME@medscape.net.
To access activities, users will need:
- A computer with an Internet connection.
- Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.
- Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback.
- Occasionally other additional software may be required such as PowerPoint or Adobe Acrobat Reader.
In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
NACCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity awards 1.25 contact hours.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hours.
North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion, as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
The planning committee comprises: Andrew J. Cutler, MD, Jon W. Draud, MS, MD, Andrew Penn, RN, MS, NP, CNS; and Kristin Della Volpe, Raquel Gaerlan, Randy Robbin, John Savage, Jessica Steuerman, and Sue Ellen Touma, PhD, NACCME.
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
Andrew J. Cutler, MD, is a consultant for Abbott, Alkermes, AstraZeneca, Bristol-Myers Squibb, Forest Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Novartis, Noven, Otsuka, Pfizer, Sunovion, Supernus, and Takeda. He is also a speaker for Abbott, AstraZeneca, Bristol-Myers Squibb, Forest, Janssen, Lilly, Merck, Novartis, Otsuka, Pfizer, and Sunovion. Dr. Cutler receives research grant funding from Abbott, Alkermes, AstraZeneca, Bristol-Myers Squibb, Forest, Janssen, Johnson & Johnson PRD, Lilly, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Sunovion, Supernus, and Takeda.
Jon W. Draud, MS, MD, is a national advisory board and speakers bureau member of, as well as a consultant for, Angelini-Biopharm, AstraZeneca, Cephalon Inc., Eli Lilly and Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, Merck, Novartis, Pfizer Inc., sanofi-aventis, Sunovion, Takeda, Wyeth Pharmaceuticals.
Andrew Penn, RN, MS, NP, CNS, has disclosed no relevant financial relationships with any commercial interests.
Ms. Volpe, Ms. Gaerlan, Mr. Robbin, Mr. Savage, Ms. Steuerman, and Dr. Touma have disclosed no relevant financial relationships with any commercial interests.
This activity has been independently reviewed by CME Peer Review, LLC.
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2012 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
This activity is supported by an educational grant from Sunovion Pharmaceuticals, Inc.